Ophthalmology Innovation Summit @ AAO

Lasik procedures head up discussions at AAO meeting

Frank Apicella — Wed, 28 Nov 2012 16:56:40 +0000

The post Lasik procedures head up discussions at AAO meeting appeared first on Ophthalmology Innovation Summit @ AAO.

LIVE BLOG RECAP: Ophthalmology Innovation Summit

Frank Apicella — Wed, 28 Nov 2012 15:58:27 +0000

The post LIVE BLOG RECAP: Ophthalmology Innovation Summit appeared first on Ophthalmology Innovation Summit @ AAO.

Eyeworld Article OIS/AAO

karin — Thu, 18 Oct 2012 12:47:29 +0000

The post Eyeworld Article OIS/AAO appeared first on Ophthalmology Innovation Summit @ AAO.

Eyeworld | June, 2012 | OIS @ ASCRS

Frank Apicella — Sun, 26 Aug 2012 07:25:24 +0000

The post Eyeworld | June, 2012 | OIS @ ASCRS appeared first on Ophthalmology Innovation Summit @ AAO.

Medical Device Daily | April 27th, 2012 | OIS @ ASCRS

Frank Apicella — Sun, 26 Aug 2012 07:48:54 +0000

The post Medical Device Daily | April 27th, 2012 | OIS @ ASCRS appeared first on Ophthalmology Innovation Summit @ AAO.

Mark B. Abelson

Frank Apicella — Fri, 15 Jun 2012 17:33:33 +0000

Dr. Mark Abelson is an internationally recognized expert in ocular pharmacology, clinical ophthalmic pharmacokinetics and external eye diseases including dry eye and allergy. He is Clinical Professor of Ophthalmology at Harvard Medical School.

Dr. Abelson founded Ora, Inc., the leading ophthalmic clinical research organization central to the development of 32 currently marketed products. Ora’s models are used internationally in the regulatory approval process.

His MD was earned at McGill University and clinical and research Fellowship was done at Massachusetts Eye and Ear and Schepens. Numerous awards include: ARVO Silver Fellow, Irving H. Leopold lecturer, AAO Honor Award, Alcon Hall of Fame, and Distinguished Alumnus from Harvard Medical School.

Dr. Abelson has written over 300 publications, including his text, Allergic Diseases of the Eye and editor of the Pharmacology Section of Principles and Practice of Ophthalmology. His widely-read column “Therapeutic Topics” in Review of Ophthalmology has been running for 15 years.

The post Mark B. Abelson appeared first on Ophthalmology Innovation Summit @ AAO.

Anthony P. Adamis, MD

Frank Apicella — Tue, 28 Aug 2012 15:32:34 +0000

Anthony P. Adamis, M.D. was co-founder and CEO of Jerini Ophthalmic until the company was acquired by Shire in 2009. Prior to that, Dr. Adamis was a co-founder of Eyetech Pharmaceuticals and served as its Chief Scientific Officer until its acquisition by OSI Pharmaceuticals. Eyetech developed and obtained FDA and EMEA approval for the first anti-VEGF drug in ophthalmology. From 1992 to 2002, Dr. Adamis served on the full-time faculty of the Harvard Medical School. He was an NIH-supported principal investigator and co-director of the Retina Research Institute for Diabetic Retinopathy and Macular Degeneration at the Massachusetts Eye and Ear Infirmary. Dr. Adamis co-discovered the role that VEGF plays in new blood vessel growth and blood vessel leakage related to various diseases of the eye. He also co-discovered the role that PDGF-B plays in the regression of ophthalmic vessels, and the causal role of inflammation in the pathogenesis of diabetic retinopathy. Dr. Adamis received his M.D. with Honors from the University of Chicago and completed his ophthalmology residency at the University of Michigan. His research training in vascular biology was with Dr. Judah Folkman at the Children’s Hospital of Boston.

The post Anthony P. Adamis, MD appeared first on Ophthalmology Innovation Summit @ AAO.

Anthony P. Adamis, MD

Frank Apicella — Fri, 15 Jun 2012 16:37:43 +0000

The post Anthony P. Adamis, MD appeared first on Ophthalmology Innovation Summit @ AAO.

Noel Alpins, MD, FACS

sandra — Fri, 28 Sep 2012 19:52:59 +0000

Dr. Noel Alpins has been specialising in Cataract and Refractive Surgery since founding NewVision Clinics in Melbourne in 1996. He speaks widely on surgical techniques at national and international meetings and has been a keynote speaker and chair on many occasions. Dr Alpins was the invited RANZCO Council Lecturer at the 2010 annual scientific meeting in Adelaide and is to be the recipient of the 2012 ISRS AAO Lans Distinguished award in Chicago. He has been an Australia Day Ambassador since 2011.

He pioneered small incision cataract surgery in Victoria and is a Foundation and current member of the Excimer Laser & Research Group. Noel is also an Associate Fellow at the University of Melbourne where he completed his Diploma of Ophthalmology in 1977 and FRACS prior to commencing practice in general ophthalmology.

Dr. Alpins is on the RANZCO program committee and the editorial board of several ophthalmic information magazines and peer reviewed journals and has published widely in these. He is also an invited moderator for scientific sessions at many international conferences he attends.

He has developed new techniques for analysing astigmatism that have been adopted as the basis for evaluating laser treatments in the ophthalmic literature and regulatory authorities and has innovated new techniques for treating and analysing astigmatism that are now included on Wikipedia as the Alpins method. His most recent paper, describing a new topograhical parameter for measuring corneal astigmatism, is being published this year in the Journal of Cataract and Refractive Surgery.

Dr. Alpins is the founder and CEO of ASSORT surgical management systems, a suite of programs which includes its flagship, the ASSORT software for vector planning of treatment and outcomes analysis of cataract and refractive surgery used by colleagues internationally. The iASSORT program is interfaced with most topography devices for their expanded functionality for corneal assessment and analysis, the VectrAK program enables import and export of data for astigmatic analysis for up to 1000 cases at a time and the Web Based calculator modules from the ASSORT program for toric IOL calculation and analysis and Femto LRI surgery with others under current development. Dr Alpins holds an extensive patent portfolio, with further recent applications in process for astigmatism treatment and analysis.

The post Noel Alpins, MD, FACS appeared first on Ophthalmology Innovation Summit @ AAO.

John Barr

sandra — Tue, 23 Oct 2012 22:45:17 +0000

John Barr is executive vice president and global president of Bausch + Lomb’s Surgical business. He was named to this post in May 2012. Mr. Barr has extensive medical device and biotechnology industry experience spanning a wide variety of operational, strategy and customer-facing roles.

At Bausch + Lomb, Mr. Barr has global responsibility for the company’s full suite of ophthalmic surgical products, intraocular lenses (IOLs) and delivery systems, which include such brand names as enVista™ Crystalens®, Stellaris® PC, Storz™and VICTUS™.

Prior to Bausch + Lomb, Barr was president and CEO of AGA Medical, a pioneer of minimally invasive devices to treat structural heart defects and vascular abnormalities, and also held executive positions at V.I. Technologies and Baxter Healthcare. Barr is a graduate of the J. L. Kellogg Graduate School of Management-Northwestern University in Evanston, IL and the University of Pennsylvania in Philadelphia, PA.

The post John Barr appeared first on Ophthalmology Innovation Summit @ AAO.